However, I might just check your source on that info. Here's some clips from the manufacturers in switzerland just updated on February 6th which sugests that everythings dandy in the garden..
Geneva, Switzerland, February 6, 2006 - Serono (virt-x: SEO and NYSE: SRA) today reported its fourth quarter and full year results for the period ended December 31, 2005.
Saizen® sales increased by 13.4% (12.5% in local currencies) to $206.5m (2004: $182.1m) in 2005, and were up 2.1% (5.9% in local currencies) to $54.3m (2004: $53.2m) during the fourth quarter. In 2005, Saizen® was approved by the FDA in Adult Growth Hormone Deficiency and successfully completed the European mutual recognition procedure leading to marketing approval for the treatment of children born Small for Gestational Age (SGA) in 15 EU countries.
Serostim® sales decreased to $70.4m for the full year 2005 (2004: $86.8m) and $17.0m (2004: $22.6m) in the fourth quarter.
Key Points for Full Year 2005
Adjusted* net income up 28.4% to $565.3m and adjusted basic EPS* up 34.6% to $38.80 per bearer share and $0.97 per ADS
Significant improvement in adjusted* operating margin to 24.0% of revenues
Reported net loss of $106.1m and $7.28 per bearer share and $0.18 per ADS
Total revenues of $2,586.4m and product sales of $2,338.9m
Global Rebif® sales up 16.4% to $1,269.8m with US sales up 31.8% to $389.5m
Progress in key MS clinical trials
REGARD 1 st year of treatment completed in Rebif® vs Copaxone head-to-head study
CLARITY: oral cladribine Phase III study enrolling
Positive outcomes in two phase III programs
r-hGH in HIV-associated adipose redistribution syndrome (HARS)
IFN-beta 1a with or without ribavirin in chronic hepatitis C in Asian patients
R&D pipeline expanded through new collaborations with Biomarin, Genmab, NovImmune and Rigel
2006 outlook for high single-digit product sales growth and EPS between $42.00 and $43.40 per bearer share